---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-017478"
form_type: "8-K"
ticker: null
cik: "0001106838"
company_name: "Sonnet BioTherapeutics Holdings, Inc."
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:34:48.062728+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sonnet BioTherapeutics raises $2.0M via zero-interest convertible notes and warrants; conversion at $1.156/share

## Summary
- Completed sale of $2.0M aggregate principal convertible notes to accredited investors, plus ~$50,000 from warrants.
- Convertible notes bear no interest, mature June 30, 2026; convertible into up to 1,730,104 shares at $1.156 per share.
- Warrants to purchase 865,052 shares at $1.156 per share, exercisable for five years.
- If no subsequent offering of $5M+ within 90 days, investors can buy additional warrants and company must file registration statement.

## SEC filing metadata
- accession: 0001641172-25-017478
- form_type: 8-K
- cik: 0001106838
- company_name: Sonnet BioTherapeutics Holdings, Inc.
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1106838/000164117225017478/0001641172-25-017478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1106838/000164117225017478/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-017478
- JSON: https://secwatch.observer/filing/0001641172-25-017478.json
- Plain text: https://secwatch.observer/filing/0001641172-25-017478.txt

## Key facts
- Debt Financings
  Sonnet BioTherapeutics Holdings, Inc. incurred convertible notes of $2.0 million with certain accredited investors at no interest maturing June 30, 2026.
  - Instrument: convertible notes
  - Principal: $2.0 million
  - Counterparty: certain accredited investors
  - Rate: no interest
  - Maturity: June 30, 2026
  - Event: incurrence
  source text: On June 30, 2025, Sonnet BioTherapeutics Holdings, Inc. (the “Company”) completed a sale to certain accredited investors of convertible notes in the aggregate principal amount of $2.0 million (the “Convertible Notes”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1106838/000164117225017478/0001641172-25-017478-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.